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In-Transit Metastases
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Albertus N. van Geel, MD, PhD,* Johannes H.W. de Wilt, MD, PhD,* and
Alexander M.M. Eggermont, MD, PhD*
Objective: The aim of this study is to describe the experience with
100 TNF-based ILP for locally advanced melanoma and to deter-
mine prognostic factors for response, time to local progression, and
survival.
Methods: One hundred TNF-based ILPs were performed between
1991 and 2003 in 87 patients for whom local control by surgery of
in-transit melanoma metastases was impossible. In total, 62 iliac, 33
femoral, and 5 axillary ILPs were performed in mild hyperthermic
conditions with 2 to 4 mg of TNF and 10 to 13 mg of melphalan per
liter of limb volume.
Results: Overall response was 95%, with 69% complete response,
26% partial response, and 5% no change. Complete response rate
differed significantly for patients with IIIA disease versus IIIAB and
IV. Local and systemic toxicity was mild to moderate in almost all
cases, with no treatment-related death and one treatment-related
amputation. Five-year overall survival was 32%; local progression
occurred in 55% after a median of 16 months. In complete response
patients, 5-year survival was 42% with local progression in 52% at
a median of 22 months. Response rate and survival were signifi-
cantly influenced by stage of disease; (local progression free) sur-
vival was influenced by response rate.
Conclusions: TNF-based ILP results in excellent response rates in
this patient population with unfavorable characteristics. Response on
ILP predicts outcome in patients and reflects aggressiveness of the
tumor.
(Ann Surg 2004;240: 939–948)
In-transit metastases (IT-mets) occur in approximately 5%to 8% of patients with high-risk melanoma. The manage-
ment of IT-mets remains a challenge because it is dictated by
the biologic behavior of melanoma, especially in terms of
number and size of the lesions.1 Simple wide surgical exci-
sion is often possible if IT-mets are limited in size and
number, but fails when interval periods between new lesions
are short, when numerous or bulky lesions are present, and
when various treatment modalities, eg, radiotherapy, have
preceded surgery. Apart from local control, melanoma is
virtually refractory to all systemic treatments. Therefore,
various locoregional approaches have been proposed and
investigated. Isolated limb perfusion (ILP), developed in
1958 by Creech and Krementz,2 is the most effective regional
treatment modality, because it achieves tissue concentrations
in the affected limb of the chemotherapeutic agents that are
more than 20 times higher than what can be achieved sys-
temically.3 Melphalan (L -phenylalanine mustard L -PAM,
Alkeran®, Wellcome, London, UK) has been used as standard
drug over the years because of its efficacy and toxicity
profile.4 Melphalan-based ILP for melanoma IT-metastases is
associated with complete response (CR) rates of 40% to 50%
and overall response rates of 75% to 80%.1 Hyperthermia
may increase the response rates somewhat, but at the cost of
increased locoregional toxicity. Large melanoma lesions are
difficult to eradicate because of poor and inhomogeneous
drug uptake as with soft tissue sarcomas. Therefore, ILP
programs with melphalan alone have been abandoned for
treating irresectable soft tissue sarcomas.5 The application of
tumor necrosis factor alpha (TNF)6 changed this situation
dramatically because very large tumors were now observed to
respond very well,7 which led to successful multicenter trials
in Europe and the approval of TNF for the treatment of
irresectable extremity soft tissue sarcomas.8
TNF has also been used increasingly in combination
with melphalan for the treatment of melanoma IT-mets in
ILP. An early report on TNF-based ILPs from four centers in
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Europe showed a significant increase in CR rate up to 90%
compared with a 52% CR rate after ILPs in these centers with
melphalan alone.9 The success of TNF in the treatment of
large soft tissue sarcomas made the investigators aware early
on that TNF also improved results in particular in melanoma
patients with bulky lesions. Importantly, this clinical obser-
vation of efficacy in large tumors has been explained by
observations in our laboratory in the experimental isolated
perfusion setting in rats with advanced limb tumors. In
contrast to the poor drug uptake of melphalan after an ILP
with melphalan alone by these large tumors, it was shown
that TNF increased the uptake of melphalan selectively in the
tumor by a factor of 3 to 6 compared with ILP with melphalan
alone.10
We report here on our experience with 100 TNF-based
ILPs in patients with multiple melanoma IT-mets. We have
analyzed the data in this large group to determine prognostic
factors for response such as stage of disease, size and number
of lesions, local recurrence-free interval, and efficacy after
failing other treatments.
PATIENTS AND METHODS
Patients
Between 1991 and 2003, 100 TNF and melphalan-ILPs
were performed in 87 patients with multiple IT-mets in the
limb. Demographic data, disease presentation at time of ILP,
and ILP characteristics were obtained from a prospectively
maintained database. Patients were staged according to the
MD Anderson staging system11 and presented with stage IIIA
disease in 45 cases, stage IIIAB in 41 cases, and stage IV in
14 cases. In all cases, local control by simple surgical exci-
sion was impossible due to bulky disease, which is illustrated
by the size of the tumors (48 40 mm, 52 40 mm) and the
number of lesions (10 lesions in 43 patients, 10–50 lesions
in 32 patients, and 50 lesions in 25 patients). Besides
surgical excision of respectable tumors, 59 patients did not
undergo other treatment modalities prior to ILP, whereas 41
patients were previously treated with systemic chemotherapy,
radiotherapy, ILP with any chemotherapeutic, immunother-
apy, or a combination of the abovementioned modalities.
Patient and tumor characteristics are summarized in Table 1.
Treatment
All patients underwent an ILP via the axillary (n  5),
iliac (n  62), or femoral (n  33) approach. The method of
ILP is described in detail previously.8 In short, isolation of
the limb is achieved by clamping and canulation of the major
artery and vein, connection to an oxygenated extracorporeal
circuit, ligation of collateral vessels, and application of a
tourniquet proximal to the site of perfusion. Once tissue
temperature has reached 38°C, recombinant TNF (Boehringer
Ingelheim GmbH, Ingelheim/Rhein, Germany) is adminis-
tered via the arterial line in a dose of 2 to 4 mg. Tissue
temperatures are stabilized between 38°C and 39.5°C, and
leakage monitoring is performed by using a precordial scin-
tillation probe to detect leakage of radiolabelled albumin
injected to the perfusion circuit.12 After 30 minutes, melpha-
lan is added to the perfusate in a dose of 10 mg/L for leg and
13 mg/L for arm perfusions. In 23 ILPs performed between
1991 and 1994, interferon  (IFN) was added to the schedule
according to trial prescriptions consisting of the subcutaneous
injection of 0.2 mg of IFN on days 2 and 1 prior to ILP
and injection of 0.2 mg of IFN during the ILP procedure into
the arterial line before administration of TNF. The median
dose of melphalan was 89.2 mg (mean 94.5, range 39–140),
the median dose of TNF was 4 mg (mean 3.69, range 2–4),
and all 23 IFN-ILPs were performed with 0.2 mg of IFN. At
the end of the perfusion period, a washout procedure using 2
to 4 L of a dextrane and/or electrolyte solution is performed.
In patients undergoing an iliac perfusion, an iliac lymph node
dissection is performed; an axillary lymph node dissection is
performed in patients undergoing an axillary ILP. In patients
with palpable nodal disease in the groin, an ilio-inguinal
TABLE 1. Patient and Tumor Characteristics of 87 Patients
Undergoing 100 TM-ILPs
Characteristics
No. of
Patients
Sex Female 60 (69%)
Male 27 (31%)
Age (years),
median  range
62 (25–90)
Stage IIIA 45
IIIAB 41
IV 14
Location Arm 5
Leg 95
No. of tumors 10 43
10–50 32
50 25
Size of largest
lesion (mm)
40 mm 48
40 mm 52
Prior treatment None 59
XRT 4
CT 8
ILP 21
Immuno 3
Combination 5
TM-ILP indicates isolated limb perfusion with tumor necrosis factor and
melphalan; XRT, radiotherapy; CT, chemotherapy; ILP, isolated limb per-
fusion; Immuno, immunotherapy.
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lymph node dissection is performed in the same operative
session as the ILP but before executing the ILP.
Evaluation of Response and Toxicity
Acute local toxicity of the ILP procedure was classified
according to Wieberdink et al in the following manner:13 (I)
no reaction; (II) slight erythema or edema; (III) considerable
erythema or edema with some blistering, slightly disturbed
motility permissible; (IV) extensive epidermolysis or obvious
damage to the deep tissues, causing definite functional dis-
turbance and threatening or manifest compartmental syn-
drome; and (V) reaction that may necessitate amputation.
Response evaluation was performed 2 to 4 and 8 weeks after
ILP by clinical examination, and after that at 3-month regular
intervals for the first 2 years and at longer intervals thereafter.
Response rates were reported according to WHO criteria14 in
which CR is the complete disappearance of all lesions with no
new areas of disease appearing within the field of ILP. Partial
response (PR) is defined as a reduction of 50% to 99% of the
total tumor size; no change (NC) is recorded if 50% of the
total tumor size responds.
Recurrence of tumor within the extremity after a CR, or
progression of the lesions and the appearance of new lesions
after a PR or after NC, is reported as local progression.
Statistical Evaluation
Overall survival (OS) and time to local/systemic pro-
gression (TTLP/TTSP) were defined as time from ILP to
death, local progression, and systemic progression, respec-
tively, and estimates were made according to the method of
Kaplan and Meier.15 Disease-free survival is defined as the
time from CR to local progression, systemic progression, or
death, whichever occurs first. We evaluated the prognostic
value of some baseline factors for these three endpoints
(TTLP/TTSP and OS) with Cox regression. The hazard ratio
belonging to each factor in Table 3 is defined as the hazard of
the second category divided by the hazard in the first cate-
gory. We also evaluated the prognostic value of some base-
line factors on achievement of CR with logistic regression.
The odds ratio of each factor is the odds of CR achievement
in the second category divided by the odds of CR achieve-
ment in the first category. The prognostic factors that we
included were the following: sex, age, site of tumor, stage of
disease, size of largest lesion, and number of lesions. This list
represents all previously reported studies on prognostic fac-
tors after ILP.16–21 After univariate analysis, all these factors
were included in a multivariate model. We used a stepwise
backward algorithm to exclude factors without prognostic
value with a significance level of 5%. After obtaining the
final model, we evaluated the additional prognostic value of
CR after perfusion. However, it must be noted that a prog-
nostic model with response on perfusion applies only to
patients after perfusion, whereas the model without response
on perfusion can also be applied to patients before perfusion.
All tests were performed at a significance level of 5%.
RESULTS
Sixty female and 27 male patients with a median age of
62 years (mean 61, range 25–90) had multiple IT-mets in the
upper (n  5) or lower (n  95) extremity. A melphalan-ILP
was performed to achieve local control in all 87 patients; 26
ILPs were performed in patients who had undergone one or
multiple ILPs previously during the course of their disease
either in our institution (n  13, melphalan-ILPs) or in the
TABLE 2. Local and Systemic Toxicity
Local toxicity
Wieberdink12 Grade I Grade II Grade III Grade IV Grade V
15% 54% 27% 3% 1%
Systemic toxicity
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Neurologic* 93% 7% 0% 0% 0%
Liver* 98% 0% 2% 0% 0%
Renal* 99% 0% 1% 0% 0%
Haematologic* 99% 0% 0% 0% 1%
Temp 38°C 38–39°C 39–40°C 40°C, 24 h 40°C, 24 h
37% 26% 31% 6% 0%
Shock† Absent Present
98% 2%
Hrs indicates hours.
*WHO criteria.13
†Support of vasopressors needed.
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referring hospital (n  13). In total, 100 TNF-based ILPs 
IFN were performed in our institution.
Leakage and Toxicity
There was no or minor leakage of the drugs in 93 ILPs
(median leakage 0%). Eight ILPs had leakage percentages of
10% to 32%. Toxicity in these 8 cases was limited to transient
hypotension in 2 patients for which vasopressor support was
given; in 1 patient, a grade IV leucopenia was observed that
lasted only for 1 day and that did not need any type of
intervention. Local toxicity after ILP was mild to moderate
(Wieberdink grade IIIII) in 81%. A Wieberdink I (no
reaction) was seen after 15 procedures and in 3 patients a
grade IV local toxicity occurred, with the need of performing
a fasciotomy in 1 patient. One patient with IT-mets in the
lower leg experienced extensive rhabdomyolysis of the upper
leg, necessitating an amputation. This reaction was classified
as Wieberdink grade V (Table 2).
Response Rates and Limb Function
The overall response rate was 95%, with 69 CRs (69%),
26 PRs (26%), and 5 NCs (5%). The proportion of patients
reaching CR presenting with stage IIIA disease (82%) dif-
fered from those presenting with stage IIIAB (63%) and stage
IV disease (43%) (Table 3). These differences showed a
significant correlation between CR and stage of disease (IIIA
vs. IIIAB, P  0.053; IIIA vs. IV, P  0.004; IIIAB vs. IV,
P 0.184). Limb function was assessed in all 87 patients and
was unaffected with respect to standard daily activities in 84
of them. One case of moderate function loss was recorded,
and 2 amputations had to be performed—1 because of a
Wieberdink grade V local toxicity (see above) and 1 because
of severe arteriosclerosis, which required a below-knee am-
putation more than 1 year after the ILP.
Local Progression
Local progression occurred after 55 ILPs (55%), at a
median time of 16 months. Median TTLP of patients after CR
was 22 months versus 6 months for patients after PR or NC
(P  0.001) (Fig. 1). There was more rapid progression of
disease in patients with a high (10) number of IT-mets (P
0.001), consistent in both uni- and multivariate analysis
(Tables 3 and 4, Fig. 2). No difference in TTLP was observed
for stage IIIA versus stage IIIAB patients (P  0.12).
Systemic Progression
During follow-up, systemic progression occurred after
71 ILPs. Median time to TTSP was 14 months and differed
significantly between stage IIIA (55 months) and stage IIIAB
TABLE 3. Univariate Analysis of Clinical Prognostic Factors for CR Achievement, Local Progression and Survival
Variable CR Local progression Survival
OR (P value) HR (P value) HR (P value)
Sex (female* vs. male) 0.56 (0.20) 1.04 (0.91) 1.89 (0.02)
Age (60* vs. 60) 0.74 (0.50) 1.56 (0.11) 1.49 (0.11)
Location of lesions (three strata: Lower arm/leg*
vs. Upper arm/leg1 vs. Total limb2)
0.68 (0.49)1 1.66 (0.35)2 0.82 (0.62)1 0.80 (0.49)2 1.04 (0.92)1 0.87(0.64)2
Stage of disease (three strata: IIIA* vs. IIIAB1
vs. IV2)
0.37 (0.05)1 0.16 (0.006)2 1.54 (0.13)1 0.78 (0.69)2 1.96 (0.01)1 9.78 (0.001)2
Size of largest lesion (Ø4 cm* vs. 4 cm) 0.58 (0.21) 1.08 (0.78) 2.01 (0.005)
Number of lesions (10* vs. 10) 0.64 (0.31) 2.85 (0.001) 0.96 (0.86)
IFN (no* vs. yes) 1.84 (0.27) 0.82 (0.52) 0.58 (0.08)
Prior ILP treatment (no* vs. yes) 1.30 (0.60) 1.34 (0.31) 0.57 (0.06)
Date of perfusion (1st 50 ILPs* vs. 2nd 50) 0.35 (0.02) 1.86 (0.02) 1.62 (0.07)
CR achieved (no* vs. yes) NA 0.25 (0.001) 0.27 (0.001)
*Reference group.
CR indicates complete response; OR, odds ratio; HR, hazard ratio; IFN, interferon gamma; NA, not applicable.
FIGURE 1. TTLP by response on ILP; x-axis: time in months;
y-axis: cumulative proportion.
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(9 months, P  0.001) patients (Fig. 3). Other prognostic
factors for systemic progression included sex (P  0.001),
size of the largest lesion (P  0.001), prior ILP treatment
(P  0.003), and ILP response (P  0.001). Prognostic
factors for systemic progression were consistent with prog-
nostic factors for survival.
Survival
The overall actuarial 5-year survival rate was 32% (5
SE); median survival was 25 months. Survival was influenced
by stage of disease, sex, size of the largest tumor, and
previous ILP-treatment (Table 3). After multivariate analysis,
stage of disease, and age of the patient remained prognostic
variables for survival (Table 4, Fig. 4). Disease-free survival
was estimated for stage IIIA/IIIAB patients. At 3 years,
disease-free survival was 16% and was significantly different
between stage IIIA (32%) and IIIAB (0%, P  0.008)
patients.
When the achievement of CR after ILP was added to
the prognostic factor analysis in the multivariate model, it
was shown to be of significance in TTLP (P 0.001) without
influencing the prognostic value of number of lesions (P 
0.001). For survival, the achievement of CR is of significant
prognostic value, reducing the impact of age of the patient.
Five-year OS for patients with a CR after ILP was 42%
versus 5% for PR/NC-patients (P  0.001) (Fig. 5). Be-
cause stage of disease itself is a prognostic factor for re-
sponse, the effect of response was evaluated for each stage of
disease (Table 5) and remained significant, especially in stage
IIIA patients.
Influence of IFN, Previous ILP Treatment, and
Tumor Bulk
IFN-: No significant difference in CR-rate was found
between patients receiving a melphalan-ILP with or without
IFN (78% vs. 66% respectively, P 0.274). Neither could an
additive effect of IFN be detected for TTLP (P  0.521) or
for survival corrected for stage of disease (P  0.149).
TABLE 4. Multivariate Analysis of Clinical Prognostic Factors for CR Achievement, Local Progression and Survival Prior to ILP
Endpoint Variable N Haz ratio p 95% CI
CR Stage of disease IIIA* 45 1
IIIAB 41 0.375 0.053 0.139–1.013
IV 14 0.162 0.006 0.044–0.598
Local progression Number of lesions 10* 43 1
10 57 2.854 0.001 1.539–5.293
Survival Stage of disease IIIA* 45 1
IIIAB 41 2.005 0.011 1.174–3.423
IV 14 11.654 0.001 4.640–29.272
Age (years) 60* 47 1
60 53 1.738 0.033 1.047–2.887
CR indicates complete response; ILP, isolated limb perfusion; Haz ratio, hazard ratio; CI, confidence interval.
*Reference group.
FIGURE 2. TTLP by number of lesions; x-axis: time in months;
y-axis: cumulative proportion.
FIGURE 3. TTSP by stage of disease; x-axis: time in months;
y-axis: cumulative proportion; IIIA  stage IIIA disease; IIIAB 
stage IIIAB disease; IV  stage IV disease.
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Prior ILP: Prior ILP treatment, a typical indication for
a repeat ILP with TNF, had no effect on CR rate (P  0.601)
or TTLP (P  0.312). The 26 patients who received multiple
ILPs had a 5-year survival of 44% versus 28% for patients
receiving a single treatment (P  0.059).
Tumor bulk: Because the experience with TNF-based
ILP in soft tissue sarcomas clearly indicated that the addition
of TNF induced impressive responses in large tumors in
contrast to the experience with melphalan alone, we gradually
changed our inclusion criteria for a TNF-based ILP and
decided only to offer this treatment to patients with bulky
disease or to patients who had failed previous perfusion(s).
For this reason, we retrospectively analyzed the results of the
first 50 ILPs versus the last 50. The tumor burden and stage
of disease of the latter group differed significantly from the
first (Table 6). Both CR rate (80% vs. 58%; P  0.017) and
TTLP (20 vs. 8 months; P  0.021) were significantly lower
in the last 50 ILPs. Survival was also shorter in the latter
group (45 vs. 21 months), but this difference just failed to
reach statistical significance (P  0.066).
DISCUSSION
We report here on 100 TNF-based ILPs in melanoma
patients out of a total of 350 TNF-based ILPs that we
performed in our institution during the period from 1991
though July 2003. In patients with melanoma IT-mets, the
procedure is associated with a close to 100% response rate in
a patient population that has significantly shifted towards
more bulky disease and pretreatments over the years. This
patient population is considerably less likely to respond to
treatment than the patient population of “all patients that
present with IT-mets” that we used to elect for a melphalan-
only ILP in the past, even when IT-mets were limited in
number and size. This single institution experience further
underscores that in the expert setting, the procedure is very
safe. TNF can be used in high doses without a single case of
treatment-related mortality; there were no cases of grade 4
systemic toxicity except for a single case in which significant
leakage occurred and leukocytes dropped below 1.0 for a
single day. In such a setting, there is no need for other than
standard cardiovascular monitoring peroperatively, no need
FIGURE 4. OS by stage of disease; x-axis: time in months;
y-axis: cumulative proportion; IIIA  stage IIIA disease; IIIAB 
stage IIIAB disease; IV  stage IV disease.
TABLE 5. Influence of Response Rate on Survival After ILP
Stage of
disease CR N Haz ratio p
IIIA yes* 37 1
no 8 5.016 0.001
IIIAB yes 26 2.189
no 15 4.130 0.115
IV yes 6 8.158
no 8 41.035 0.041
CRcomplete response, Haz ratiohazard ratio
FIGURE 5. OS by response on ILP; x-axis: time in months;
y-axis: cumulative proportion.
TABLE 6. Influence of Tumor Bulk and Stage of Disease
1st 50
ILPs
2nd 50
ILPs p
Size of largest lesion (Ø) 4 cm 60% 36%
4 cm 40% 64% 0.016
Number of lesions 10 50% 36%
10 to
50
34% 30%
50 16% 34% 0.105
Stage of disease IIIA 60% 30%
IIIAB 36% 46%
IV 4% 24% 0.002
CR rate 80% 58% 0.017
TTLP (median, months) 20 8 0.021
Survival (median, months) 45 21 0.066
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for standard use of vasopressors, or for standardly having
patients in the intensive care unit postoperatively.22
The present series shows a CR rate of 69%, which is
within the range of CR rates reported in previously published
smaller series.6,18,23–25We identified stage of disease as a
prognostic factor for response with the most prominent dif-
ference in IIIA versus IIIAB/IV patients, which is in line with
the literature on melphalan-based ILP.16–19 This probably
reflects a difference in aggressiveness of melanoma biology
in these patient categories, further exemplified by significant
differences in survival. This hypothesis is sustained by the
observation that during the course of melanoma progression,
the ability of melanoma cells to express so-called death
receptors diminishes.26 TNF receptor and TNF-related apo-
ptosis inducing ligand, 2 examples of these receptors, play
key roles in the acquired resistance of melanoma cells to
undergo TNF-mediated apoptosis; whereas early-phase mel-
anoma appears to use TNF pathways to undergo programmed
cell death, late-phase melanoma does not.27 Response to
treatment therefore is an indicator of the tumor phenotype,
which itself is of influence on patient survival.
Potentially, it may also reflect a difference in immuno-
competence between these patient categories that differ
greatly because of the absence or presence of lymph node
metastases and/or visceral metastases. In our laboratory, we
showed an attenuation of tumor response to ILP in leukocyte-
depleted rats,28 which corresponds well to the report on the
role of an early and rapid invasion of tumor lesions after a
TNF-based ILP by neutrophils.29 Furthermore, we reported in
our observation of tumor lesions in patients after ILP that
eosinophils and macrophages (“melanophages”) play an im-
portant role in the delayed-type reaction to melphalan-ILP.30
Results of ILP treatment are often presented in overall
response rates. Our prognostic factor analysis shows that
especially the CR rate is of imminent importance, because it
significantly affects both TTLP and survival. In fact, the
marked difference in TTLP between CR and PR/NC patients
identifies the period that the patient is without any need of
locoregional treatment. We therefore specifically analyzed
the group of patients with IIIA/IIIAB disease and a PR after
ILP, because these patients progress rapidly in the limb and
therefore might need repeat locoregional treatment. Of these
23 patients, however, only 5 patients lived for more than 9
months without presenting distant metastases, and they re-
ceived additional treatment (among which, 2 repeat ILPs).
This indicates that response on ILP selects those patients with
more aggressive disease, which is sustained by the prognostic
influence of response rate on OS, especially when corrected
for stage of disease. The 42% 5-year survival rate in CR
patients, which make up the large majority of patients (69%),
is quite substantial and compares favorably with most com-
monly reported survival rates for this patient category (23–
47%).31 This underscores the importance of the treatment and
shows that it is a worthwhile intervention.
Patient Selection
Since the introduction of TNF in the ILP setting, it has
been discussed which patient subgroup would profit the most
from addition of this cytokine.32 The early experience of four
European centers showed that the treatment of all patients
with IT-mets, irrespective of number of tumors or size of the
lesions, increased the complete response rate from 52% to
91%.9 Yet the notion that the clearest benefit was seen in the
patients population with bulky tumors that previously was
known to be very poorly responsive to melphalan-based ILP
was already obvious through our experiences in the multi-
center trials in sarcoma patients since 1991, and it affected
over the years the patient selection in our institution. We
managed patients with small tumors and a small number of
tumors increasingly by repeated excisions and vaccine pro-
tocols, and we offered TNF-based ILP more and more exclu-
sively to patients with a high tumor burden. In this patient
category with highly unfavorable characteristics, analyzed
separately as the second 50 ILPs in our series, CR rate was
still 58%. This is still superior to the response rate in the
historical group of patients treated with melphalan alone
without such unfavorable patient selection,9 and it is similar
to observations made in the United States. In an interim
analysis of a randomized trial by Fraker et al, TNF-based ILP
was shown to be of significant benefit in patients with a high
tumor load, increasing the CR rate from 19% for melphalan-
ILP to 58% in melphalan(IFN)-ILP.33 Moreover, Rossi et
al reported recently in a series of 20 melanoma patients with
a high tumor burden a CR rate of 70% after TNF-based ILP.34
We demonstrate in this series of patients that the median
TTLP of 16 months exceeds the median of TTSP of 14
months in the overall patient population. It underscores that
systemic metastases present frequently in stage IIIA and
IIIAB populations and that an ILP should be reserved for
patients who run out of simple management options such as
excision of a few lesions or participation in nontoxic vacci-
nation protocols for (multiple) small lesions that do not
present clear local morbidity. Those patients without local
morbidity that still progress systemically can thus be spared
the ILP intervention. Moreover, in case these patients respond
to a vaccine, they most likely will do so also at systemic
disease sites at the cost of little toxicity and no surgical
intervention. This policy shift has occurred over the 12-year
period described here and has led to a patient population with
significantly more advanced disease locally in the second
bracket of 50 ILPs (after 1996). It is important to realize that
even in this patient population, the CR rate of 58% is still
higher than the 52% CR rate in our previous experience with
melphalan alone in patients with clearly less extensive
disease.9
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A second indication for melphalan-ILP is failure after
previous ILP-therapy.35 In our recent study, 26 ILPs were
performed for recurrences in the limb after previous ILP
treatment (13 ILPs after prior ILP elsewhere, 13 repeat
melphalan-ILPs in our institution). The overall response rate
of repeat ILP was 96% (CR 73%, PR 23%, NC 3%). This did
not differ from the primary ILPs in our series, and no
increased toxicity was observed, as opposed to previous
reports on the outcome of repeat melphalan-based ILP.36 This
observation underscores the efficacy of a TNF-based ILP in
the repeat-ILP setting and thereby its indication.
Toxicity
Local toxicity after TNF-based ILP in our series was
moderate to severe (grade III-IV) in 31 ILPs (31%), which
compares with reported percentages in TNF or melphalan-
based ILP.37 A reintervention by amputation or fasciotomy
occurred in only two patients. Local toxicity is reported to be
directly correlated with the incidence of long-term morbidity
(tissue fibrosis, muscle atrophy, and limb malfunction).38 In
our patient population, however, the rate of limb function loss
was markedly low, even in the 27 patients older than 75 years
and in the 26 patients with multiple ILP treatments.
Systemic toxicity is directly correlated with leakage of
the chemotherapeutics to the systemic circulation.8,22,39,40 In
the present situation of leakage-free ILPs, the systemic tox-
icity is mostly limited to fever in the first 24 hours postop-
eratively, which can be easily avoided by the immediate
postoperative application of indomethacin and/or paraceta-
mol. Furthermore, patients commonly show a period of 6 to
10 hours of slightly elevated circulation due to a drop in
peripheral resistance, which is compensated by a mild tachy-
cardia and a small drop in blood pressure, easily managed by
a generous intravenous fluid infusion policy, and does not
require the standard use of vasopressors. The feared systemic
adverse reaction to TNF—a systemic inflammatory response
syndrome with a major drop in blood pressure that requires
the administration of vasopressors—was not observed in any
of our patients. Only in two patients, both with substantial
leakage during the ILP, did the blood pressure drop lead to
the administration of vasopressors at a mild dose of 3 to 6
g/kg for a maximum duration of 36 hours. The absence of
any major toxicity is due to a number of factors: first,
adequate leakage control in virtually all patients; second, and
this is of crucial importance, we have a policy of ample
hydration of the patient during ILP and for the first 12 to 24
hours after ILP. This policy assures that all our patients have
adequate diuresis to keep the period of high circulating TNF
levels post-ILP as short as possible.22 Eight ILPs in our series
had a leakage percentage above 10% (up to 32%), but in only
one patient did this lead to a systemic reaction by elevated
liver enzymes, elevated urea, and leucopenia, which are all
easily managed with normal conservative measures. We do
not use and therefore do not advocate the standard use of
Swann-Ganz catheters, vasopressors, or postoperative stay in
the intensive care. In our experience, neither systemic nor
local toxicity is significantly enhanced in TNF-based ILP
compared with melphalan-based ILPs.
In conclusion, our results demonstrate the very high
efficacy of TNF-based ILP in melanoma patients both in
terms of local control of disease and of survival. Outcome is
influenced by stage of disease, reflecting the aggressiveness
of the melanoma. Complete response to ILP selects within
each stage of disease those patients with relatively favorable
characteristics. In our experience, the use of TNF increases
the CR rate, especially in patients with a high tumor burden
and in those having failed previous therapy. Local and sys-
temic safety profile of the TNF-based ILP is so good that in
the expert setting, a TNF-based ILP does not need a standard
approach that differs from a melphalan-based ILP. The pro-
cedure should be considered in all cases of limb-threatening
tumors or in situations where simple surgical procedures to
obtain local control fail. Currently, the procedure is the most
efficacious one to obtain local control and achieve limb
salvage in such conditions.41
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Discussion
PROF. BOREL RINKES: I have a question on the mecha-
nism. How does TNF  melphalan act, what mechanism is
involved that causes this synergistic antitumor effect?
DR. EGGERMONT: The synergy is based on at least two
separate effects, an immediate effect and a late effect. More-
over, the synergy is observed in the treatment of large tumors,
tumors that because of their pathophysiology do not respond
to chemotherapy alone because of impaired drug uptake, even
in the ILP setting. Our laboratory program has really eluci-
dated a number of these crucial data. Originally, it was
thought that the eradication of the tumor-associated vascula-
ture by the TNF  melphalan combination was the main
event, as had been demonstrated clearly by the angiograms
pre- and post-ILP in patients. However, it was only in the
laboratory that we were able to show that the early and
immediate event may be even more important. The immedi-
ate effect of TNF on the tumor is a change in the pathophys-
iology of the perfusion of the tumor. The TNF opens up
nonfunctional vessels, and this vasodilation diminishes the
shunting of blood flow around the tumor and enhances the
blood flow through the tumor and slows it down. This leads
to a much more homogenous perfusion of the tumor and
enhances thereby drug uptake 5- to 6-fold, as we have
demonstrated. This is an enormous difference, and such an
intensification of drug concentrations in the tumor can never
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ever be achieved by any type of intensification of systemic
chemotherapy. With systemic chemotherapy, you can inten-
sify 1.2 to 1.3 times, and then you will need stem cell support.
So in the TNF melphalan ILP setting, this pharmacological
enhancement of drug uptake will lead to massive tumor cell
kill, and the later effects are characterized by the tumor-
selective eradication of the tumor vasculature, which adds to
the tumor necrosis. On slides you can see the shedding and
destruction of the endothelial cell lining of the vessels; it only
happens in the tumor-associated vessels. This leads to throm-
bosis and it leads vasodestruction. Tumor vessels are much
more sensitive to the TNF, not only by up-regulation of the
TNF receptors, but also by the lack of anchor mechanisms
like the alphaVbeta3 and therefore they do not have the
survival signals as opposed by the normal lining of the
normal vasculature. It is this selective expression that gives
you the window of opportunity for your therapeutic effect.
DR. BOREL RINKES: Is TNF  melphalan better than
melphalan alone in vitro culture systems?
DR. EGGERMONT: Only about one third of the tumor cells
lines are sensitive to TNF in vitro. So apparently the major
effects are indirect effects mediated in vivo by host mecha-
nisms. So to study these mechanisms, you need to work in
vivo. For in vitro models, you need at least sophisticated
matrix models, and in these the TNF  chemotherapy com-
bination shows the same type of efficacy enhancement that
you see in vivo. In cell cultures you will miss those effects
because it is by interactive host-mediated mechanisms and it
is not only by direct mechanisms.
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